亚胺培南与头孢哌酮/舒巴坦治疗恶性血液病患者医院获得性肺炎疗效评价

Comparison of clinical efficacy of imipenem and cefoperazone/sulbactam in treatment of hospital-acquired pneumonia in patients with hematologic malignancies

目的评价亚胺培南和头孢哌酮/舒巴坦治疗恶性血液病发生医院获得性肺炎患者的临床疗效及安全性,为临床治疗提供参考依据。方法回顾性分析2011年7月-2014年7月220例恶性血液病发生医院获得性肺炎患者,按抗菌药物使用分为试验组与对照组,试验组116例患者使用亚胺培南治疗;对照组104例患者使用头孢哌酮/舒巴坦治疗;比较两组恶性血液病患者治疗后临床疗效及细菌消除率,数据采用SPSS 17.0软件进行统计分析。结果患者治疗总有效率试验组为81.9%、对照组为80.8%,两组比较差异无统计学意义;病原菌清除率试验组为78.2%、对照组为84.0%,两组比较差异无统计学意义;两组抗菌药物使用中不良反应均较轻。结论亚胺培南与头孢哌酮/舒巴坦用于治疗恶性血液病患者医院获得性肺炎疗效确切且安全,可作为治疗重度医院肺部感染临床经验性药物首选。

OBJECTIVE To compare the curative effect of imipenem and cefoperazone/sulbactam in treatment of hospital-acquired pneumonia in patients with hematologic malignancies and to provide a reference for clinical treatment.METHODS A retrospective analysis of the clinical efficacy of hospital-acquired pneumonia in 220 patients with hematologic malignancies from Jul.2011 to Jul.2014 was conducfed.Based on the use of antibacterial drugs,116 patients using imipenem were divided into treatment group,while the other 104 patients using cefoperazone/sulbactam were divided into the control group.After treatment,clinical efficacy and the bacteria elimination rate of the hematologic malignancies in patients with hospital acquired of the two groups were compared.RESULTS The total clinical effective rate was 81.9% for the treatment group and 80.7% for the control group.There was no significant difference between the two groups.The bacteria elimination rate was 78.2% and 84% respectively in treatment group and control group.There was no significant difference.Few adverse events occurred in both groups.CONCLUSIONThe application of imipenem and cefoperazone/sulbactam in patients with hematologic malignancies are of great efficacy and safety,especially in severe lung infections.It is a drug of choice for clinical empirical.